Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The goal of this observational study is to improve the detection of dementia with Lewy bodies (DLB) and its prodromal phases, as well as advancing our current understanding of biological mechanisms and therapeutic options. The data is acquired at cognitive clinics in Stockholm (Sweden) and combined with national and international data to increase statistical power, representativeness and replication of results. Participants undergo collection of clinical assessments, neuroimaging and fluid biomarkers.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:
• At least one core clinical feature of dementia with Lewy bodies such as visual hallucinations, parkinsonism, cognitive fluctuations, or probable REM sleep behaviour disorder.
Locations
Other Locations
Sweden
Karolinska University Hospital
RECRUITING
Stockholm
Contact Information
Primary
Daniel Ferreira, Docent, Senior Lecturer
daniel.ferreira.padilla@ki.se
+46720128047
Time Frame
Start Date: 2020-01-01
Estimated Completion Date: 2031-03-01
Participants
Target number of participants: 600
Treatments
MCI
The MCI group consists of participants diagnosed with mild cognitive impairment (MCI), in accordance with clinical consensus criteria. This can be of MCI-Lewy body type, MCI-Alzheimer´s disease type, MCI-Parkinson´s disease type, or MCI-other type
DLB
The DLB group consists of participants diagnosed with dementia with Lewy bodies (DLB) according to clinical criteria from the international consensus.
Cognitively Unimpaired
The Cognitively Unimpaired group refers to those participants without indications of cognitive impairment, including two subgroups: healthy controls and people with subjective cognitive decline
Other Dementias
The Other Dementias group includes participants diagnosed with forms of dementia other than dementia with Lewy bodies (e.g., Alzheimer's disease, Parkinson's disease dementia), as well as those with dementia not otherwise specified.
Related Therapeutic Areas
Sponsors
Leads: Karolinska Institutet